Results 151 to 160 of about 6,967 (165)
Some of the next articles are maybe not open access.
Tolvaptan efficacy and drug-drug interactions
Minerva Endocrinologica, 2020Discussion of the presence of drug-drug interactions that may affect the efficacy of tolvaptan in hyponatremic patients affected by ...
Giampaolo Corti +8 more
openaire +4 more sources
DMW - Deutsche Medizinische Wochenschrift, 2013
Vasopressin-V 2 -Rezeptor-Antagonisten reduzierten in fruheren Studien die Zystenlast und hatten protektive Effekte auf die Nierenfunktion. Torres et al. fuhrten nun eine multizentrische, randomisierte, kontrollierte, doppelblinde Phase-III-Studie zur Wirksamkeit und Sicherheit von Tolvaptan durch.
openaire +2 more sources
Vasopressin-V 2 -Rezeptor-Antagonisten reduzierten in fruheren Studien die Zystenlast und hatten protektive Effekte auf die Nierenfunktion. Torres et al. fuhrten nun eine multizentrische, randomisierte, kontrollierte, doppelblinde Phase-III-Studie zur Wirksamkeit und Sicherheit von Tolvaptan durch.
openaire +2 more sources
[From hyponatremia to tolvaptan].
Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2014Hyponatremia is the electrolytic disorder that is observed most frequently in hospitalized patients. Itinfluences prognosis in the short, mid and long term. Although many cases are asymptomatic, hyponatremia can cause severe neurological symptoms, depending on the amount of serum sodium reduction and on the rapidity with which it occurs.
CERNARO, VALERIA +4 more
openaire +2 more sources
American Journal of Health-System Pharmacy, 2013
The bioavailability of a crushed tolvaptan tablet suspended in water and administered by nasogastric (NG) tube was compared to the bioavailability from the tablet administered whole.In a randomized crossover study, 28 healthy adults received a single 15-mg dose of tolvaptan on two occasions (one dose given as an intact tablet swallowed whole and the ...
Kim L. R. Brouwer +7 more
openaire +3 more sources
The bioavailability of a crushed tolvaptan tablet suspended in water and administered by nasogastric (NG) tube was compared to the bioavailability from the tablet administered whole.In a randomized crossover study, 28 healthy adults received a single 15-mg dose of tolvaptan on two occasions (one dose given as an intact tablet swallowed whole and the ...
Kim L. R. Brouwer +7 more
openaire +3 more sources
Cost effectiveness of tolvaptan
BMJ, 2011Amin and Meeran refer to the relative expense of tolvaptan, one of the new vasopressin 2 receptor antagonists.1 They suggest that it has little benefit over existing treatments but fail to mention …
openaire +2 more sources
Tolvaptan for Volume Management in Heart Failure
Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2019Volume management in acute decompensated and chronic heart failure (HF) remains a significant challenge. Although progress has been made in the development of mortality‐reducing neurohormonal regimens in the reduced ejection fraction population, no clinical trial has yet demonstrated anything more than symptomatic relief or biomarker reduction with ...
Erik G. Gunderson +4 more
openaire +3 more sources
Human Sulfotransferases Enhance the Cytotoxicity of Tolvaptan
Toxicological Sciences, 2015Tolvaptan, a vasopressin receptor 2 antagonist used to treat hyponatremia, has recently been reported to be associated with liver injury. Sulfotransferases (SULTs) have been implicated as important detoxifying and/or activating enzymes for numerous xenobiotics, drugs, and endogenous compounds.
Priyanka Chitranshi +5 more
openaire +3 more sources
Synthesis of the major metabolites of Tolvaptan
Chinese Chemical Letters, 2012Tolvaptan is a nonpeptide arginine vasopressin (AVP) V2-receptor antagonist and used in the treatment of heart failure, cirrhosis, syndrome of inappropriate antidiuretic hormone secretion or other high-volume capacity of hyponatremia. The metabolites of tolvaptan are mainly produced by CYP3A4, including two major compounds named DM-4103 and DM-4107 ...
Yong Wu +5 more
openaire +2 more sources
Hyponatremia, Heart Failure, and the Role of Tolvaptan
Postgraduate Medicine, 2012Hyponatremia-usually defined by serum sodium < 135 mEq/L-is common in heart failure (HF); it remains unclear whether it worsens HF or is merely a marker of more severe disease. Hyponatremia may develop from causes besides HF and symptoms may be mistakenly attributed to HF. Hyponatremia correction may be required for optimal HF management in some cases,
John B O'Connell, Addis Alemayehu
openaire +2 more sources